Introduction
V600E, melanoma, melanomas
PROLIFERATION, SOLID TUMORS, MELANOMA, MELANOMAS
The mitogen-activated protein kinase/extracellular signal regulated kinase (MAPK/ERK) pathway, comprising RAS, RAF, MEK and ERK proteins, couples extracellular growth factor signals from receptor tyrosine kinases to intracellular responses, modulating cell proliferation and survival [In around 70–90% of Type I inhibitors are not indicated for the treatment of patients with BRAF wild-type melanoma or melanomas harboring oncogenic Tovorafenib (also known as DAY101, TAK-580, MLN2480, BIIB024) is an investigational, oral, central nervous system-penetrant, selective, small molecule pan-RAF kinase type II inhibitor. It shows potent activity against BRAF V600E and oncogenic BRAF fusions, suppressing the activity of both monomeric and dimeric forms [The aim of this phase 1 dose escalation study was to evaluate the safety profile and to determine the maximum tolerated dose (MTD) of tovorafenib given as monotherapy on once every other day (Q2D) and once weekly (QW) dosing regimens to patients with relapsed or refractory solid tumors. In a subsequent dose expansion phase of the study, the safety and preliminary antitumor activity of tovorafenib were further evaluated in cohorts of patients with 